BlueCross and BlueShield of Montana Medical Policy/Codes
Beta Amyloid Imaging with Positron Emission Tomography (PET) for Alzheimer’s Disease
Chapter: Radiology
Current Effective Date: September 24, 2013
Original Effective Date: December 11, 2012
Publish Date: September 24, 2013
Revised Dates: August 21, 2013

The diagnosis of Alzheimer’s disease (AD) is divided into three categories: possible, probable, and definite AD. (1) A diagnosis of definite AD requires post-mortem confirmation of AD pathology, including the presence of extracellular beta-amyloid plaques and intraneuronal neurofibrillary tangles in the cerebral cortex. (2) Probable AD dementia is diagnosed clinically when the patient meets core clinical criteria for dementia and has a typical clinical course for AD. A typical clinical course is defined as an insidious onset, with the initial and most prominent cognitive deficits being either amnestic or non-amnestic, e.g., language, visuospatial, or executive function deficits, and a history of progressively worsening cognition over time. A diagnosis of possible AD dementia is made when the patient meets the core clinical criteria for AD dementia but has an atypical course or an etiologically mixed presentation.

Mild cognitive impairment (MCI) may be diagnosed when there is a change in cognition, but not sufficient impairment for the diagnosis of dementia. (3) Features of MCI are evidence of impairment in one or more cognitive domains, and preservation of independence in functional abilities. In some patients, MCI may be a predementia phase of AD. Patients with MCI may undergo ancillary testing (e.g., neuroimaging, laboratory studies, and neuropsychological assessment) to rule out vascular, traumatic, and medical causes of cognitive decline and to evaluate genetic factors. Because clinical diagnosis can be difficult, particularly early in the course of disease, there has been considerable interest in developing biomarkers for AD. One biomarker that is being evaluated is amyloid plaque density in the brain detected in vivo by PET.

A radioactive dye (florbetapir) has been developed that binds to beta-amyloid and can be detected in vivo with positron emission tomography (PET). This technology is being evaluated to detect beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and/or other causes of cognitive decline.

PET images biochemical and physiological functions by measuring concentrations of positron-emitting chemicals in the body region of interest. Radiopharmaceuticals used for beta-amyloid imaging may be generated in a cyclotron or nuclear generator and introduced into the body by intravenous injection. A number of 11C and 18F-labeled PET radiopharmaceuticals have been investigated for imaging brain beta-amyloid. (4) However, due to the short half-life (20 minutes), 11C radiotracers are not convenient for commercialization. Several 18F beta-amyloid radiotracers are currently in phase II and III clinical trials. (5) To date, only florbetapir (18F-AV-45) has received approval for clinical use by the U.S. Food and Drug Administration (FDA).

Regulatory Status

In 2012, the FDA approved florbetapir (Amyvid™, Avid Radiopharmaceuticals, a subsidiary of Eli Lilly) as a radioactive dye for visualization of amyloid plaque in the brain. The FDA document prepared for the advisory committee meeting indicated that while florbetapir may detect pathology, there could be no claim of disease detection, since beta-amyloid aggregates can be found in cognitively normal elderly individuals as well as patients with AD. (6)

Amyvid™ is indicated “for PET [positron emission tomography] imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.”


Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply.  If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.


Blue Cross Blue Shield of Montana (BCBSMT) considers beta-amyloid imaging with positron emission tomography (PET) experimental, investigational and unproven for any indication, including but not limited to Alzheimer’s disease.


Assessment of a diagnostic technology typically focuses on the following 3 domains; 1) technical performance; 2) diagnostic performance (sensitivity, specificity, and positive and negative predictive value) in relevant populations of patients, such as those with mild cognitive impairment or suspected Alzheimer’s disease (AD); and 3) demonstration that the diagnostic information can be used to improve patient outcomes. The gold standard for the diagnosis of AD is post-mortem neuropathologic examination. In the absence of comparisons with the gold standard, long-term clinical follow-up (e.g., conversion from mild cognitive impairment [MCI] to probable AD) may be used as a surrogate standard to evaluate the diagnostic performance of beta-amyloid imaging with positron emission tomography (PET).

Beta-amyloid imaging may be particularly helpful for the future study of novel therapeutic agents that target amyloid plaques. However, current clinical purposes of testing for beta-amyloid plaque density would be to improve diagnostic accuracy (e.g., rule out AD) or predict conversion from MCI to AD. In general, evidence of a health benefit or clinical utility from testing requires demonstration of:

  • incremental improvement in diagnostic or prognostic accuracy over current practice, and
  • that incremental improvements lead to improved health outcomes (e.g., by informing clinical management decisions), and
  • that these outcomes may be obtained (i.e., are generalizable) outside of the investigational setting.

Literature Review

Technical Performance: Evidence on technical performance of this test should demonstrate that the test measures what it is intended to, i.e., beta-amyloid plaque. The best evidence on this would be direct comparison with a gold standard test for measuring amyloid plaque, which is histopathologic examination of tissue. Other important measures of technical performance are the reliability of testing, including both test-retest reliability and interobserver reliability in reading test results.

Data on technical performance of the test was included in an FDA-regulated study, which was published in 2011. (6, 7) This study was a Phase III multicenter trial with 2 separate cohorts. These cohorts were an autopsy cohort and a young, cognitively intact cohort. The autopsy cohort was drawn from 152 subjects who had a projected life expectancy of 6 months or less. Thirty-five individuals passed away and were autopsied within 12 months of PET imaging; 29 were included in the primary efficacy analysis. This cohort was composed of 9 subjects (31%) who were not cognitively impaired, 2 (7%) who were mildly impaired, 13 (45%) with a clinical diagnosis of AD, and 5 (17%) with a clinical diagnosis of a non-AD dementia.

All patients had direct measurement of amyloid burden by histopathologic examination, and 52% met the pathologic criteria for AD. A significant correlation of 0.78 was found between amyloid burden in the brain measured by Amyvid and the gold standard of histopathology, however, there was not an exact match between the 2 measures. The correlation between quantitative whole-brain florbetapir image scores and post-mortem silver stain was 0.71. In the young controls (specificity cohort to evaluate false positives), the primary efficacy endpoint was the exclusion of amyloid in 47 young subjects who were negative for the apolipoprotein E ε4 (APOE4) allele, randomly interspersed with PET scans of 40 subjects in the autopsy cohort. The study achieved specificity of 100% in this cohort, although it is noted that the young controls are outside of the intended use population.

Reproducibility of the readings was assessed using 3 trained readers who were blinded to the clinical information. Using a binary scale (positive or negative for amyloid), sensitivity ranged from 55% to 90% for the 3 readers, and in 24-45% of the images (depending on the sample), at least one reader would have had a different interpretation of amyloid status from the other readers. (6) Subsequent reanalysis for publication used the majority rating of 3 nuclear medicine physicians as the primary outcome variable, resulting in 96% agreement between florbetapir-PET images and histopathologic results in the 29 subjects in the primary analysis cohort. (7)

Conclusions: Evidence on technical performance is mainly from the FDA-sponsored study. A strength of this study is the comparison of florbetapir imaging with the gold standard of post-mortem histopathology. Limitations include the small sample size, a majority rating for assessing diagnostic accuracy, and having only 2 patients in the mildly impaired category, which is the population for whom the test is most likely to be used. Evidence from this study indicates that the agreement between histopathology and beta-amyloid testing by PET is good but not perfect. There is evidence for inter-observer variability in reading the test; using a majority of 2/3 readers leads to a high agreement with histopathology.

Diagnostic Performance: The FDA-regulated study also included some information on diagnostic performance of the test. Using the majority consensus of three independent reviewers as the final test reading, sensitivity and specificity was calculated compared to the gold standard of histopathology. (7) Of 15 subjects who met pathologic criteria for AD, 14 had positive florbetapir scans (sensitivity of 93%). Of the 14 subjects who did not meet pathologic criteria for AD, all 14 had negative scans (specificity of 100%). Scans from all of the young subjects (27 APOE4+ and 47 APOE-) were negative. Exploratory analysis indicated that in 3 subjects (20%), the clinical diagnosis did not match with the final autopsy diagnosis. These measures of diagnostic accuracy are limited by the patient population, which is not representative of the population that the test is intended to be used for, and the use of a majority reading based on 3 independent experts, which is not likely to be used in clinical care.

An industry-funded multicenter study by Fleisher et al. pooled data from 4 phase I and II trials of florbetapir-PET imaging for a total of 210 participants, including 68 subjects with probable AD, 60 subjects with MCI, and 82 older unimpaired controls. (8) Quantitative standard uptake value ratio (SUVRs) thresholds were determined from the Phase III trial described above. Although there were significant differences in mean SUVRs across groups, there was considerable overlap in the range of values. The percentage of subjects meeting threshold levels of amyloid with clinical AD, MCI and cognitively healthy controls was 80.9%, 40.0%, and 20.7%, respectively. The percentage of subjects with any identifiable florbetapir signal was 85.3%, 46.6%, and 28.1%, respectively. Among healthy controls, the percentage of subjects with any florbetapir positivity increased linearly by age, ranging from 11.8% for subjects 55 to 60 years of age to 41.7% for subjects 81 years of age or older. APOE4 carriers in the control group had about twice the percentage of florbetapir positivity as noncarriers, although this comparison did not reach statistical significance.

In 2012, Camus et al. reported the diagnostic performance of florbetapir-PET in a clinical setting. (9) Included were 13 subjects with AD, 12 with MCI, and 21 older unimpaired controls. PET images were assessed visually by 2 readers who were blinded to any clinical information and quantitatively by the SUVR of cortical regions compared to the cerebellum. Sensitivity and specificity were calculated based on clinical diagnosis as the comparison standard. Agreement in visual analysis between the 2 readers gave a kappa value of 0.71. Comparing visual assessment with the initial clinical diagnosis, 11 of 13 AD patients (85%), 6 subjects with MCI (50%) and 13 of 21 control subjects (60%) had positive scans, resulting in sensitivity of 84.6% and a specificity of 38.1% for discriminating AD patients from control subjects. A quantitative assessment of the global cortex SUVR showed a sensitivity of 92.3% and specificity of 90.5% at a cut-off value of 1.12 (ROC [receiver operating characteristics] area under the curve 0.894). Although the study is limited by the small number of subjects and the use of clinical diagnosis as a reference standard, these results suggest a high number of false positives with visual assessment of the images. In addition, quantitative analysis was not able to differentiate subjects with MCI from unimpaired controls.

Conclusions: Evidence on the diagnostic performance of beta-amyloid testing is limited, and the available studies all have methodologic limitations that limit the validity of reported results. As a result, it is not possible to determine the sensitivity and specificity of testing. Some evidence suggests that there are a high number of false positive results in patients without AD. However, the FDA study reports high specificity, so the true rate of false positives is uncertain. Further high-quality studies using populations of patients that represent those presenting in clinical care are needed to better define the diagnostic performance of this test.

Clinical Outcomes: No trials have been identified that reported health outcomes following florbetapir-PET imaging, thus there is no direct evidence for clinical utility.

Possible clinical uses of beta-amyloid testing could include confirming the diagnosis of AD in order to begin medications at an earlier stage, or ruling out AD, which may lead to further diagnostic testing to determine the etiology of dementia and/or avoidance of anti-Alzheimer’s medications that would be unnecessary.

Since the sensitivity and specificity of beta-amyloid testing has not yet been established, it is not possible to determine an indirect chain of evidence that would indicate that health outcomes are improved. Because of the presence of beta-amyloid in elderly patients who do not have AD, it is not likely that the test will have a high positive predictive value, and therefore it may have limited utility in confirming AD. It is possible that the negative predictive value of testing may be high and that the test may be useful in ruling out AD. If this is true, it is not certain how many patients would benefit from additional testing to determine etiology, or whether a substantial number of patients would avoid unnecessary medications that would otherwise be given.

Conclusions. Evidence on clinical utility, i.e. that health outcomes are improved by testing, is lacking. There are no studies that report on clinical outcomes following testing. The diagnostic accuracy of testing is too uncertain to determine whether testing is likely to impact management and/or lead to improved outcomes.

Ongoing Clinical Trials

A search of the online site in May 2012 identified a number of trials on amyloid imaging with PET. Of particular interest are the following:

  • An industry-sponsored Phase III open-label study to evaluate the efficacy and safety of florbetaben (BAY94-9172) PET imaging for detection/exclusion of cerebral beta-amyloid compared to postmortem histopathology (NCT01020838). This study has an estimated enrollment of 216 subjects with completion of the primary outcome measure in 2011 and final study completion in 2014.
  • An industry-sponsored Phase III open-label study to compare the brain uptake of flutemetamol with brain amyloid levels determined post-mortem (NCT01165554). The study has an estimated enrollment of 100 subjects with completion in 2012.
  • An industry-sponsored Phase III open-label study to assess the prognostic usefulness of flutemetamol for identifying subjects with amnestic MCI who will convert to clinically probable AD (NCT01028053). The study has an estimated enrollment of 225 subjects with completion estimated for January 2013.


Literature on the use of florbetapir-PET imaging to aid in the diagnosis of patients with suspected Alzheimer’s disease is limited. The pivotal Phase III trial, although to be commended for its use of the gold standard of histopathology, has a number of limitations including small sample size, use of a majority rating of 3 physicians, and having few patients in the mildly impaired category. This study reported a moderately high correlation of amyloid plaque with histopathologic examination. The sensitivity and specificity of this test have not yet been adequately determined in an appropriate population, including a larger number of patients with mild cognitive impairment.

The clinical utility of this technology is uncertain. The test is not likely to be useful for confirming AD in patients who present with cognitive impairment. It may have a role in ruling out AD, but this has yet to be established with certainty. Questions also remain about the use of this test outside of the investigational setting, particularly regarding the accuracy of visual interpretation of images and how best to apply this test in routine clinical practice.

Practice Guidelines and Position Statements

2011 Guidelines from the National Institute on Aging and Alzheimer’s Association on the diagnosis of mild cognitive impairment and dementia due to Alzheimer’s disease recommend the use of biomarkers, including beta-amyloid imaging with PET, only in research settings. (1, 3) Reasons for this recommendation are that more research needs to be done to ensure that the criteria that include the use of biomarkers have been appropriately designed, there is limited standardization of biomarkers from one locale to another; and access to biomarkers may be limited in community settings.

The Alzheimer’s Association has indicated qualified support for the availability of florbetapir. (10) The statement includes the following: “On one hand, FDA approval of this product will expand the clinical and research opportunities for amyloid imaging by making this brain imaging tool more widely available to the field. On the other hand, the fact that all of the potential uses of this product are not crystal clear tempers our enthusiasm. Again, additional research is needed to clarify the role of florbetapir-PET imaging in Alzheimer’s.” The Alzheimer’s Association has convened a task force with the Society of Nuclear Medicine to develop recommendations for the use of amyloid imaging.


Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps. 

ICD-9 Codes
92.11, 294.10, 294.11
ICD-10 Codes
F01.50-F03.91, C030YZZ 
Procedural Codes: 78811, 78814, A4641, A9586
  1. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3):263-9. Available at: (accessed May 2012).
  2. Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8(1):1-13. Available at: (accessed May 2012).
  3. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3):270-9. Available at: <> (accessed May 2012).
  4. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin Nucl Med 2011; 41(4):283-99.
  5. Vallabhajosula S, Solnes L, Vallabhajosula B. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new? Semin Nucl Med 2011; 41(4):246-64.
  6. U.S. Food and Drug Administration. FDA Advisory Committee briefing document: Peripheral and central nervous system drugs advisory committee. 2011. Available at: (accessed May 2012).
  7. Clark CM, Schneider JA, Bedell BJ et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305(3):275-83.
  8. Fleisher AS, Chen K, Liu X et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68(11):1404-11.
  9. Camus V, Payoux P, Barre L et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012; 39(4):621-31.
  10. Alzheimer's Association. Alzheimer's Association statement on FDA approval of florbetapir (Amyvid). 2012. Available at: (accessed May 2012).
  11. Beta Amyloid Imaging with Positron Emission Tomography (PET) for Alzheimer's Disease. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (2012 June) RAdiology 6.01.55
August 2012 Policy created with literature review through April 2012; considered investigational.
August 2013 Policy formatting and language revised.  Policy statement unchanged.  Added HCPCS code A9586.
®Registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. ®LIVE SMART. LIVE HEALTHY. is a registered mark of BCBSMT, an independent licensee of the Blue Cross and Blue Shield Association, serving the residents and businesses of Montana.
CPT codes, descriptions and material only are copyrighted by the American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS Restrictions Apply to Government Use. CPT only © American Medical Association.
Beta Amyloid Imaging with Positron Emission Tomography (PET) for Alzheimer’s Disease